Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pegaspargase-induced pancreatitis.

O A Alvarez1, G Zimmerman

  • 1Division of Hematology-Oncology, Department of Pediatrics, Loma Linda University School of Medicine, Loma Linda, California 92350, USA.

Medical and Pediatric Oncology
|March 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kinetic study of strong shock waves in fully ionized plasmas.

Physical review. E·2026
Same author

Particle-in-cell simulations of burning inertial confinement fusion capsule implosions.

Physical review. E·2025
Same author

Direct Evidence of Multispecies Hydrodynamics in Ignition-Scale Hohlraums.

Physical review letters·2025
Same author

Inverse bremsstrahlung absorption rate for super-Gaussian electron distribution functions including plasma screening.

Physical review. E·2024
Same author

Hohlraum Reheating from Burning NIF Implosions.

Physical review letters·2024
Same author

Increased Ion Temperature and Neutron Yield Observed in Magnetized Indirectly Driven D_{2}-Filled Capsule Implosions on the National Ignition Facility.

Physical review letters·2022
Same journal

Kaposiform hemangioendothelioma and therapy with interferon-alpha.

Medical and pediatric oncology·2003
Same journal

Importance of informed consent in offering to return research results to research participants.

Medical and pediatric oncology·2003
Same journal

Tumor lysis syndrome and neuroblastoma.

Medical and pediatric oncology·2003
Same journal

High incidence of brain tumors of childhood in Hungary between 1989 and 2001.

Medical and pediatric oncology·2003
Same journal

Surviving childhood cancer: what next? Issues under consideration at the After Completion of Therapy (ACT) clinic in India.

Medical and pediatric oncology·2003
Same journal

Local control in childhood extremity sarcomas: salvaging limbs and sparing function.

Medical and pediatric oncology·2003
See all related articles

Pegaspargase, used for childhood leukemia, was linked to a higher incidence of pancreatitis compared to native L-asparaginase. Clinicians should monitor for this serious side effect in patients receiving pegaspargase treatment.

Area of Science:

  • Oncology
  • Pediatric Hematology
  • Pharmacology

Background:

  • Pegaspargase is a chemotherapy agent used in treating hematological malignancies.
  • Pancreatitis is a potential adverse event associated with L-asparaginase-based therapies.

Purpose of the Study:

  • To determine the incidence of pancreatitis in pediatric patients treated with pegaspargase.
  • To compare the pancreatitis risk between pegaspargase and native E. coli L-asparaginase.

Main Methods:

  • Retrospective analysis of patients treated with pegaspargase (May 1996-April 1998).
  • Clinical evaluation, serum amylase/lipase levels, and radiographic imaging were used to diagnose pancreatitis.
  • Comparison group received native E. coli L-asparaginase during the same period.

Related Experiment Videos

Main Results:

  • 18% (9/50) of patients receiving pegaspargase developed pancreatitis, with symptoms appearing within 15 days.
  • Seven patients experienced severe toxicity (grades 3-4) due to pancreatitis.
  • Pancreatitis incidence was significantly higher with pegaspargase (18%) versus native L-asparaginase (1.9%, P=0.007).

Conclusions:

  • Pegaspargase is associated with a notably higher incidence of pancreatitis.
  • Healthcare providers should be vigilant for pancreatitis in patients undergoing pegaspargase therapy.
  • Further investigation into the mechanism and management of pegaspargase-induced pancreatitis is warranted.